

Mr. Henning Gädeke, Chair of the Global Health EDCTP3 Joint Undertaking Governing Board
c/o Dr. Michael Makanga, Executive Director, Global Health EDCTP3 Joint Undertaking
Global Health EDCTP3 Joint Undertaking
56 – 60 Avenue de la Toison d’Or
1060 Brussels
Belgium

29 August 2025

Letter of endorsement

Dear Sir/Madam,

On behalf of Aerogen Limited, IDA Business Park, Dangan Galway, Ireland, [VAT Reg No. 8277354F] and in accordance with Council Regulation (EU) No 2085/2021 of 19th November 2021 establishing the joint undertakings under Horizon Europe and specifically Article 9 therein, I hereby submit an application to become a contributing partner to the Global Health EDCTP3 Joint Undertaking (Global Health EDCTP3 JU).

Aerogen is a pioneer in the development of the vibrating mesh nebuliser with, until recently, a strong focus on the acute and critical care patient. The vibrating mesh nebuliser has been demonstrated to be compatible with a huge range for formulations for inhalation across the full range of patient types. Over our 25-year history we have focused on exploiting our technology to enable cost effective, high precision delivery of therapeutics and prophylactics.

We have a keen interest in vaccine delivery specifically, having been the delivery system for the world’s first commercially approved inhaled vaccine, Convidecia Air for COVID-19. During the COVID-19 pandemic we dosed more than 30 million patients, and have since continued to build on that experience, as well as that experience gained through collaboration with the World Health Organisation on previous mass vaccination programs focused on inhaled measles vaccines in children.

Our delivery technology is the go-to for current and past leading inhaled vaccine, including those conducted by our partners in this consortium. Our first in world “vaccination station” system for inhaled delivery of vaccines has resulted in a dramatic reduction in the cost per dose of a vaccine, superior patient compliance, ease of deployment, ease of use and most significantly, had demonstrated that inhaled vaccines may be dose sparing. We have through our own research and development and our multiple collaborations throughout the world with leading researchers consistently demonstrated that targeted delivery of the vaccine to the respiratory mucosa requires significantly less dose than other routes of administration.

As has been our target in this development, I firmly believe that all of those potential advantages can only serve to further close the immunisation gap, improving equitable, safer and more cost-effective vaccines to those in greatest need. Those also being mutually shared objectives with the Global Health EDCTP3 JU.

In this program Aerogen look forward to working with our partners to leverage our respective expertise and technologies to advance protection against tuberculosis. The design of the program is

such that we, in the most efficient way possible build on the existing proof of concept and lay the foundations for better vaccine strategies.

We look forward to participating across the program, but Aerogen's focus shall be on the clinical trials execution, as well as taking the opportunity to take on board stakeholder's views around this new delivery modality. This work in combination will build to de-risk future follow on projects, but also to build the streamlined foundations and template for other inhaled vaccine programs.

Within Aerogen, we estimate the total value of this contribution to be in excess of EUR 225,000 corresponding to in-kind contributions as specified below:

- | | |
|--|-----------|
| • In-kind contribution for personnel salaries: | € 125,000 |
| • In-kind contributions for delivery systems: | € 75,000 |
| • Others: | € 25,000 |

We confirm the following:

1. We will comply with the Horizon Europe Regulation (EU) No 2021/695; Council Regulation (EU) No 2085/2021 establishing the joint undertakings under Horizon Europe; the Model Grant Agreement for Horizon Europe and applicable Global Health EDCTP3 JU rules, including the relevant work programmes and in particular the call conditions therein.
2. We will keep all information received in the context of our involvement as contributing partner to the Global Health EDCTP3 JU confidential. This confidentiality obligation applies in particular but is not limited to the areas of Global Health EDCTP3 JU call topic preparation and publication, proposal submission and evaluation, and consortium formation. We further understand that this obligation strictly prohibits the release of confidential information to any legal entities save where specifically authorised by Global Health EDCTP3 JU. Internal dissemination of information within our organisation will be done on the basis of the "need-to-know" principle.
3. We are confident of our ability to fulfil the above commitments and further confirm our understanding that the Global Health EDCTP3 JU will allocate resources to the above topic based on these commitments.
4. The value of our contribution will be based on costs calculated in accordance with Article 6 of the Horizon Europe Model Grant Agreement.
5. We accept that additional modalities regarding the provision of our contribution may be defined in subsequent agreements or documents, such as a funding agreement and topic text.

Yours faithfully,

Signed by:

29-Aug-2025

 Signer Name: Ronan MacLoughlin
Signing Reason: I am the author of this document
Signing Time: 29-Aug-2025 11:58:01 PM BST
Dr Ronan MacLoughlin, PhD MBS
2C85FAF33FDE491597B4CE7ADAAE78FF
Director R&D Science and Emerging Technologies